# A Phase 2, Randomized, Double-Blind, Dose Escalation Study in Postoperative Pain Open Inguinal Herniorrhaphy

> **NCT05080959** · PHASE2 · COMPLETED · sponsor: **Cali Pharmaceuticals LLC** · enrollment: 105 (actual)

## Conditions studied

- Inguinal Herniorrhaphy

## Interventions

- **DRUG:** CPL-01
- **DRUG:** Naropin 150 MG Per 20 ML Injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05080959
- **Lead sponsor:** Cali Pharmaceuticals LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-28
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-06-10
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2022-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05080959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05080959, "A Phase 2, Randomized, Double-Blind, Dose Escalation Study in Postoperative Pain Open Inguinal Herniorrhaphy". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT05080959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*